Global Alzheimer’S Diagnostics Market
Alzheimer’s Disease Diagnostics Market Size And Forecast
Alzheimer’s Disease Diagnostics Market was valued at USD 3.01 Billion in 2019 and is projected to reach USD 5.23 Billion by 2027, growing at a CAGR of 7.30% from 2020 to 2027.
Global Alzheimer’s Disease Diagnostics Market Outlook
Alzheimer’s disease is a growing epidemic. In the present case scenario, more than 5.8 million Americans have Alzheimer’s disease. By 2050, it is expected that nearly 14 million (approx.) Americans over age 65 could be living with the disease unless scientists develop new approaches for preventing or curing it. However, estimation by the U.S. Census based on high-range projections of population growth suggest that this number may be as high as 16 million. Increasing age is known to be the greatest risk factor for Alzheimer’s disease. It is not part of normal aging, however, as the population begins to grow older the likelihood of Alzheimer’s disease increases. A study carried out by Mayo Clinic found that annually there were two new diagnoses per 1,000 people ages 65 to 74, 11 new diagnoses per 1,000 people ages 75 to 84, and 37 new diagnoses per 1,000 people age 85 and older.
Global Alzheimer’s Disease Diagnostics Market Competitive Landscape
The “Global Alzheimer’s Disease Diagnostics Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Johnson & Johnson, F. Hoffmann-La Roche Ltd, Quanterix, Sysmex, Eli Lilly & Company, and Others.
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.